Experimental stroke drug also shows promise for people with Lou Gehrig's disease

Neuroscientists have found that early muscle impairment related to Lou Gehrig's disease, also called amyotrophic lateral sclerosis, or ALS, in mice is proportional to the degree of damage to the blood-spinal cord barrier, which protects the central nervous system from toxins. Repairing damage to and restoring the blood-spinal cord barrier's integrity with an experimental neurovascular medicine being studied in human stroke patients appears to delay disease progression.